Aurinia Pharmaceuticals (AUPH) Payables (2016 - 2026)

Aurinia Pharmaceuticals has reported Payables for 11 years, with the latest figure at $2.7 million in Q1 2026.

• For the quarter ending Q1 2026, Payables fell 36.94% year-over-year to $2.7 million; the trailing twelve-month figure through Mar 2026 stood at $2.7 million (down 36.94% YoY), and the FY2025 full-year result was $3.3 million, down 36.13% from the prior year.
• Payables for Q1 2026 stood at $2.7 million, down from $3.3 million in the prior quarter.
• The five-year high for Payables was $56.8 million in Q3 2024, with the low at $2.2 million in Q3 2025.
• Historically, Payables has averaged $27.2 million across 5 years, with a median of $32.4 million in 2022.
• Annual changes were most pronounced in 2022 — Payables soared 82.7% — and 2025, when it slumped 96.1%.
• Aurinia Pharmaceuticals' Payables stood at $40.0 million in 2022, then plunged by 89.18% to $4.3 million in 2023, then gained by 19.88% to $5.2 million in 2024, then plunged by 36.13% to $3.3 million in 2025, then decreased by 19.68% to $2.7 million in 2026.
• The last three Payables figures came in at $2.7 million (Q1 2026), $3.3 million (Q4 2025), and $2.2 million (Q3 2025), per Business Quant data.